Frank Ruffo
2021
In 2021, Frank Ruffo earned a total compensation of $3.3M as Chief Financial Officer at Aclaris Therapeutics, a 302% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $177,551 |
|---|---|
| Option Awards | $1,873,125 |
| Salary | $401,700 |
| Stock Awards | $798,792 |
| Other | $11,600 |
| Total | $3,262,768 |
Ruffo received $1.9M in option awards, accounting for 57% of the total pay in 2021.
Ruffo also received $177.6K in non-equity incentive plan, $401.7K in salary, $798.8K in stock awards and $11.6K in other compensation.
Rankings
In 2021, Frank Ruffo's compensation ranked 4,107th out of 12,415 executives tracked by ExecPay. In other words, Ruffo earned more than 66.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,107 out of 12,415 | 67th |
Division Manufacturing | 1,694 out of 5,508 | 69th |
Major group Chemicals And Allied Products | 699 out of 2,378 | 71st |
Industry group Drugs | 622 out of 2,099 | 70th |
Industry Pharmaceutical Preparations | 438 out of 1,549 | 72nd |
Source: SEC filing on April 21, 2022.
Ruffo's colleagues
We found four more compensation records of executives who worked with Frank Ruffo at Aclaris Therapeutics in 2021.